1
|
Barik D, Dash P, Uma PI, Kumari S, Dash M. A Review on Re-Packaging of Bisphosphonates Using Biomaterials. J Pharm Sci 2021; 110:3757-3772. [PMID: 34474062 DOI: 10.1016/j.xphs.2021.08.028] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2021] [Revised: 08/26/2021] [Accepted: 08/27/2021] [Indexed: 12/19/2022]
Abstract
The need for bone repair and insight into new regeneration therapies as well as improvement of existing regeneration routes is constantly increasing as a direct consequence of the rise in the number of trauma victims, musculoskeletal disorders, and increased life expectancy. Bisphosphonates (BPs) have emerged as a class of drugs with proven efficacy against many bone disorders. The most recent ability of this class of drugs is being explored in its anti-cancer ability. However, despite the pharmacological success, there are certain shortcomings that have circumvented this class of the drug. The mediation of biomaterials in delivering bisphosphonates has greatly helped in overcoming some of these shortcomings. This article is focused on reviewing the benefits the bisphosphonates have provided upon getting delivered via the use of biomaterials. Furthermore, the role of bisphosphonates as a potent anticancer agent is also accounted. It is witnessed that employing engineering tools in combination with therapeutics has the potential to provide solutions to bone loss from degenerative, surgical, or traumatic processes, and also aid in accelerating the healing of large bone fractures and problematic non-union fractures. The role of nanotechnology in enhancing the efficacy of the bisphosphonates is also reviewed and innovative approaches are identified.
Collapse
Affiliation(s)
- Debyashreeta Barik
- Institute of Life Sciences, Nalco Square, Bhubaneswar, 751023, Odisha, India; School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT) University, 751024, Bhubaneswar, Odisha, India
| | - Pratigyan Dash
- Institute of Life Sciences, Nalco Square, Bhubaneswar, 751023, Odisha, India; School of Biotechnology, Kalinga Institute of Industrial Technology (KIIT) University, 751024, Bhubaneswar, Odisha, India
| | - P I Uma
- Institute of Life Sciences, Nalco Square, Bhubaneswar, 751023, Odisha, India
| | - Sneha Kumari
- Institute of Life Sciences, Nalco Square, Bhubaneswar, 751023, Odisha, India
| | - Mamoni Dash
- Institute of Life Sciences, Nalco Square, Bhubaneswar, 751023, Odisha, India.
| |
Collapse
|
2
|
Wang S, Niu X, Bao X, Wang Q, Zhang J, Lu S, Wang Y, Xu L, Wang M, Zhang J. The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging. Oncol Rep 2019; 41:2636-2646. [PMID: 30896825 PMCID: PMC6448067 DOI: 10.3892/or.2019.7080] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2018] [Accepted: 03/04/2019] [Indexed: 12/29/2022] Open
Abstract
Non‑small cell lung cancer (NSCLC) metastasis commonly occurs in bone, which often results in pathological fractures. Sustained phosphoinositide‑3‑kinase (PI3K) signalling promotes the growth of PI3K‑dependent NSCLC and elevates osteoclastogenic potential. The present study investigated the effects of a PI3K inhibitor on NSCLC growth in bone and osteoclast formation, and aimed to determine whether it could control symptoms associated with bone metastasis. A bone metastasis xenograft model was established by implanting NCI‑H460‑luc2 lung cancer cells, which contain a phosphatidylinositol‑4,5‑bisphosphate 3‑kinase catalytic subunit α mutation, into the right tibiae of mice. After 1 week, the tumours were challenged with a PI3K inhibitor (buparlisib) or blank control for 3 weeks. Tumour growth and burden were longitudinally assessed in vivo via reporter gene bioluminescence imaging (BLI), small animal positron emission tomography/computed tomography (CT) [18F‑fluorodeoxyglucose (18F‑FDG)] and single‑photon emission computed tomography/CT [99mTc‑methylene diphosphonate (99mTc‑MDP)] imaging. Tibia sections of intraosseous NCI‑H460 tumours were analysed by immunohistochemistry (IHC), western blotting and flow cytometry. Dynamic weight bearing (DWB) tests were further performed to examine the improvement of symptoms associated with bone metastasis during the entire study. Administration of buparlisib significantly inhibited the progression of bone metastasis of NSCLC, as evidenced by significantly reduced uptake of 18F‑FDG, 99mTc‑MDP and BLI signals in the treated lesions. In addition, buparlisib appeared to inhibit the expression of tartrate‑resistant acid phosphatase and receptor activator of nuclear factor‑κB ligand, as determined by IHC. Buparlisib also resulted in increased cell apoptosis, as determined by a higher percentage of Annexin V staining and increased caspase 3 expression. Furthermore, buparlisib significantly increased weight‑bearing capacity, as revealed by DWB tests. The PI3K inhibitor, buparlisib, suppressed osteoclast formation in vivo, and exhibited antitumour activity, thus leading to increased weight‑bearing ability in mice with bone metastasis of lung cancer. Therefore, targeting the PI3K pathway may be a potential therapeutic strategy that prevents the structural skeletal damage associated with bone metastasis of lung cancer.
Collapse
Affiliation(s)
- Shengfei Wang
- Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China
| | - Xiaomin Niu
- Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, P.R. China
| | - Xiao Bao
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200433, P.R. China
| | - Qin Wang
- Department of Oncology, Yueyang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200437, P.R. China
| | - Jianping Zhang
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200433, P.R. China
| | - Shun Lu
- Department of Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai 200030, P.R. China
| | - Yongjun Wang
- Department of Orthopaedics and Traumatology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200000, P.R. China
| | - Ling Xu
- Department of Oncology, Yueyang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200437, P.R. China
| | - Mingwei Wang
- Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200433, P.R. China
| | - Jie Zhang
- Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China
| |
Collapse
|
3
|
Kieser DC, Mazas S, Cawley DT, Fujishiro T, Tavolaro C, Boissiere L, Obeid I, Pointillart V, Vital JM, Gille O. Bisphosphonate therapy for spinal aneurysmal bone cysts. EUROPEAN SPINE JOURNAL : OFFICIAL PUBLICATION OF THE EUROPEAN SPINE SOCIETY, THE EUROPEAN SPINAL DEFORMITY SOCIETY, AND THE EUROPEAN SECTION OF THE CERVICAL SPINE RESEARCH SOCIETY 2018; 27:851-858. [DOI: 10.1007/s00586-018-5470-y] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/05/2017] [Revised: 12/22/2017] [Accepted: 01/06/2018] [Indexed: 10/18/2022]
|
4
|
Oliveira CCD, Barros Silva PGD, Ferreira AEC, Gonçalves RP, Sousa FBD, Mota MRL, Alves APNN. Effects of dexamethasone and nimesulide on bisphosphonate-related osteonecrosis of the jaw: An experimental study. Arch Oral Biol 2017; 83:317-326. [DOI: 10.1016/j.archoralbio.2017.08.016] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2017] [Revised: 08/24/2017] [Accepted: 08/27/2017] [Indexed: 11/27/2022]
|
5
|
Brant J, Keller L, McLeod K, Hsing Yeh C, Eaton L. Chronic and Refractory Pain: A Systematic Review of Pharmacologic Management in Oncology. Clin J Oncol Nurs 2017; 21:31-53. [DOI: 10.1188/17.cjon.s3.31-53] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
6
|
Aderibigbe B, Aderibigbe I, Popoola P. Design and Biological Evaluation of Delivery Systems Containing Bisphosphonates. Pharmaceutics 2016; 9:E2. [PMID: 28035945 PMCID: PMC5374368 DOI: 10.3390/pharmaceutics9010002] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2016] [Revised: 11/24/2016] [Accepted: 11/30/2016] [Indexed: 02/06/2023] Open
Abstract
Bisphosphonates have found application in the treatment of reoccurrence of bone diseases, breast cancer, etc. They have also been found to exhibit antimicrobial, anticancer and antimalarial activities. However, they suffer from pharmacological deficiencies such as toxicity, poor bioavailability and low intestinal adsorption. These shortcomings have resulted in several researchers developing delivery systems that can enhance their overall therapeutic effectiveness. This review provides a detailed overview of the published studies on delivery systems designed for the delivery of bisphosphonates and the corresponding in vitro/in vivo results.
Collapse
Affiliation(s)
- Blessing Aderibigbe
- Department of Chemistry, University of Fort Hare, Alice Campus, Eastern Cape 5700, South Africa.
| | - Isiaka Aderibigbe
- Department of Chemical and Metallurgical Engineering, Tshwane University of Technology, Pretoria 0001, South Africa.
| | - Patricia Popoola
- Department of Chemical and Metallurgical Engineering, Tshwane University of Technology, Pretoria 0001, South Africa.
| |
Collapse
|
7
|
Hussain A, Aly A, Daniel Mullins C, Qian Y, Arellano J, Onukwugha E. Risk of skeletal related events among elderly prostate cancer patients by site of metastasis at diagnosis. Cancer Med 2016; 5:3300-3309. [PMID: 27730756 PMCID: PMC5119986 DOI: 10.1002/cam4.914] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2015] [Revised: 07/22/2016] [Accepted: 08/22/2016] [Indexed: 01/07/2023] Open
Abstract
The purpose of this study was to estimate the risk of developing skeletal-related events (SREs) based on site of metastasis at diagnosis and identify other predictors of developing SREs among metastatic prostate cancer patients. We conducted a retrospective cohort study using linked SEER (Surveillance, Epidemiology, and End Results) and Medicare data and identified men over the age of 65 with incident metastatic prostate cancer diagnosed during 2005-2009. SREs included radiation (RAD), pathological fractures (PF), bone surgery (BS), and spinal cord compression (SCC). The association between site of metastasis at diagnosis and SRE was examined using a Cox proportional hazards model that accounts for death as a competing risk. Among 4404 men (median age: 79 years) with incident metastatic prostate cancer, 44% experienced SREs at a median of 9.6 months post diagnosis. Compared to bone metastasis only, our model showed that patients were significantly less likely to develop SREs if they had LN-only metastasis at diagnosis (Sub-Hazard Ratio [SHR] 0.56; 95% Confidence Interval [CI]: 0.43-0.72) or unknown site of metastasis (SHR: 0.79; CI: 0.64-0.97). Other predictors of reduced SRE risk were age 80+ years (SHR: 0.83; CI: 0.75-0.91), non-Hispanic Black (SHR: 0.77; CI: 0.65-0.90), or being diagnosed in year 2009 (SHR: 0.85; CI: 0.72-0.99). Patients were significantly more likely to develop SREs if they received androgen deprivation therapy (SHR: 1.73; CI: 1.48-2.02) or had Gleason score 8-10 disease (SHR: 0.79; CI: 0.64-0.97). Compared to patients who present with bone metastasis only at diagnosis, patients presenting with other metastatic sites have similar risk of developing SREs, with the exception of those presenting with lymph node only metastasis who have a significantly reduced risk of SREs.
Collapse
Affiliation(s)
- Arif Hussain
- University of MarylandSchool of MedicineMarlene and Stewart Greenebaum Cancer Center BaltimoreBaltimoreMaryland
- Veterans Affairs Medical CenterBaltimoreMaryland
| | | | - C. Daniel Mullins
- Department of Pharmaceutical Health Services ResearchUniversity of MarylandSchool of PharmacyBaltimoreMaryland
| | - Yi Qian
- Amgen Inc.Thousand OaksCalifornia
| | | | - Eberechukwu Onukwugha
- Department of Pharmaceutical Health Services ResearchUniversity of MarylandSchool of PharmacyBaltimoreMaryland
| |
Collapse
|
8
|
Makino H, Nishio S, Tsubamoto H, Shimada M, Nishikawa R, Kai K, Ito K, Mizuno T, Ushijima K, Morishige KI. Treatment and prognosis of bone metastasis from cervical cancer (KCOG-G1202s). J Obstet Gynaecol Res 2016; 42:701-6. [PMID: 26935489 DOI: 10.1111/jog.12956] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2015] [Revised: 12/21/2015] [Accepted: 12/24/2015] [Indexed: 11/29/2022]
Abstract
AIM The early and precise diagnosis and proper palliative treatment of bone metastasis is important for improving the quality of life of cervical cancer patients. The aim of this study was to clarify the clinical features, treatment modalities and prognosis of bone metastasis in cervical cancer patients in Japan. METHODS The medical records of 75 cervical cancer patients with bone metastasis who were treated between January 2000 and December 2010 were retrospectively analyzed in a multi-institutional study. RESULTS Fifty-four patients (72.0%) had a single bone metastasis. Bone metastases were found in the spine (46.7%) and pelvis (42.7%). Forty-three patients (57.3%) also had extra-osseous metastases. Most of the patients received radiotherapy, chemotherapy or both, but 25 patients (33.3%) received palliative care only. Bisphosphonates were given as palliative therapy to 25 patients (33.3%). The median overall survival after the diagnosis of bone metastasis was significantly shorter in patients with extra-osseous metastases than in those without extra-osseous metastases (14 vs 5 months; P < 0.05). The survival of patients who received chemotherapy following radiotherapy or concurrent chemoradiotherapy was significantly longer than that of the patients who received palliative care. On multivariate analysis, the presence of extra-osseous metastasis was an independent predictor of survival in patients with bone metastasis from cervical cancer. CONCLUSIONS Multidisciplinary treatment might improve the prognosis of patients with bone metastasis who do not have extra-osseous lesions.
Collapse
Affiliation(s)
- Hiroshi Makino
- Department of Obstetrics and Gynecology, Gifu University, Gifu, Japan
| | - Shin Nishio
- Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan
| | - Hiroshi Tsubamoto
- Department of Obstetrics and Gynecology, Hyogo College of Medicine, Nishinomiya, Japan
| | - Muneaki Shimada
- Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Japan
| | - Ryutaro Nishikawa
- Department of Obstetrics and Gynecology, Nagoya City University, Graduate School of Medicine, Nagoya, Japan
| | - Kentaro Kai
- Department of Obstetrics and Gynecology, Oita University Faculty of Medicine, Yufu, Japan
| | - Kimihiko Ito
- Department of Obstetrics and Gynecology, Kansai Rosai Hospital, Amagasaki, Japan
| | - Tomoko Mizuno
- Department of Obstetrics and Gynecology, Gifu University, Gifu, Japan
| | - Kimio Ushijima
- Department of Obstetrics and Gynecology, Kurume University School of Medicine, Kurume, Japan
| | | |
Collapse
|
9
|
Mardas N, Busetti J, de Figueiredo JAP, Mezzomo LA, Scarparo RK, Donos N. Guided bone regeneration in osteoporotic conditions following treatment with zoledronic acid. Clin Oral Implants Res 2016; 28:362-371. [PMID: 26920844 DOI: 10.1111/clr.12810] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/24/2016] [Indexed: 01/15/2023]
Abstract
OBJECTIVES To evaluate new bone formation in calvarial critical size defects (CSD) under dense polytetrafluoroethylene (d-PTFE), microporous membranes for guided bone regeneration (GBR) in healthy, osteoporotic and osteoporotic treated with zoledronic acid (ZA) rats. METHODS Forty-eight, female, 6-month old Wistar rats were included in the study. Osteoporosis was induced by ovariectomy (OVX) and calcium-deficient diet in 32 rats. Sixteen OVX rats were treated with a single dose of Zolendronic Acid (ZA) (OZ), while 16 OVX rats received no treatment (O). The remaining 16 rats were sham-operated and used as healthy controls (C). At 6 weeks following osteoporosis induction, two 5 mm CSD were created in the parietal bones and one of them was treated with a double d-PTFE membrane. The healing periods were 30 and 60 days. New bone formation (NB) was assessed by qualitative and quantitative histological analysis. RESULTS After 30 days of healing, NB (mean% (95% CI)) was 78.9% (21), 93.1% (9.3) and 84.2% (26.9) in the membrane treated defects and 18.8% (24.1), 27.1% (7.9) and 31% (38.8) in the untreated defects of group O, OZ and C, respectively. After 60 days of healing, NB was 78.3% (14.4), 95.8% (9) and 90.1% (26.1) in the membrane treated defects and 10.8% (17.4), 51.6% (39.4) and 15.7% (12.1) in the untreated defects of group O, OZ and C, respectively. Hierarchical analysis of variance showed that treatment with ZA (P = 0.001) and the use of membrane (P = 0.000) significantly increased new bone formation while presence of osteoporosis may have reduced new bone formation (P = 0.028). CONCLUSION d-PTFE membranes for GBR promote bone healing in osteoporotic and healthy rats. Treatment with ZA may improve new bone formation in osteoporotic rats.
Collapse
Affiliation(s)
- Nikos Mardas
- Centre for Adult Oral Health, Institute of Dentistry, Bart's & The London School of Medicine & Dentistry, Queen Mary University, London, UK
| | - Juliano Busetti
- Dental School, Pontifical Catholic University of Rio Grande do Sul, Porto Alegre, Brazil
| | | | - Luis André Mezzomo
- Department of Dentistry, Federal University of Santa Catarina, Florianópolis, Brazil
| | | | - Nikolaos Donos
- Clinical Oral Research Centre, Institute of Dentistry, Bart's & The London School of Medicine & Dentistry, Queen Mary University, London, UK
| |
Collapse
|
10
|
Teng S, Yi C, Krettek C, Jagodzinski M. Bisphosphonate Use and Risk of Implant Revision after Total Hip/Knee Arthroplasty: A Meta-Analysis of Observational Studies. PLoS One 2015; 10:e0139927. [PMID: 26444555 PMCID: PMC4596810 DOI: 10.1371/journal.pone.0139927] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2015] [Accepted: 09/19/2015] [Indexed: 01/08/2023] Open
Abstract
Objective Several studies investigated the association between bisphosphonate use and the risk of implant revision after total hip or knee arthroplasty (THA or TKA); However, the findings were inconsistent. We performed this meta-analysis to evaluate the overall relative risk of such an event. Methods We searched the PubMed, EMBASE and Cochrane library databases to identify relevant publications on April 22, 2015. To calculate the pooled risk ratios (RRs) with 95% confidential intervals (CIs), a fixed- or random-effects model was applied based on the heterogeneity across studies. Results Three cohort studies and one case-control study were included in this meta-analysis. Compared with the bisphosphonate nonusers, the patients who used bisphosphonates for a long period of time had a significantly decreased risk of implant revision after THA/TKA (summary adjusted RR = 0.48, 95% CI: 0.38–0.61), and the summary adjusted RRs for the users who underwent THA and those who underwent TKA were 0.47 (95% CI: 0.36–0.61) and 0.45 (95% CI: 0.21–0.95), respectively. Conclusions Long-term use of bisphosphonates is correlated with a significantly decreased risk of implant revision after THA/TKA. However, due to limited number of the included studies, the findings of the present study should be treated with caution. More well-designed studies are required to further confirm our findings.
Collapse
Affiliation(s)
- Songsong Teng
- Department of Orthopedics, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai, P. R. China
- Department of Orthopedic Trauma, Hannover Medical School, Hanover, Germany
| | - Chengqing Yi
- Department of Orthopedics, Shanghai First People's Hospital, Shanghai Jiao Tong University, Shanghai, P. R. China
- * E-mail:
| | - Christian Krettek
- Department of Orthopedic Trauma, Hannover Medical School, Hanover, Germany
| | - Michael Jagodzinski
- Department of Orthopedic Trauma, Agaplesion ev. Hospital Bethel, Bückeburg, Germany
| |
Collapse
|
11
|
Aly A, Onukwugha E, Woods C, Mullins CD, Kwok Y, Qian Y, Arellano J, Balakumaran A, Hussain A. Measurement of skeletal related events in SEER-Medicare: a comparison of claims-based methods. BMC Med Res Methodol 2015; 15:65. [PMID: 26286392 PMCID: PMC4544826 DOI: 10.1186/s12874-015-0047-5] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2014] [Accepted: 07/10/2015] [Indexed: 12/24/2022] Open
Abstract
Background Skeletal related events (SREs) are common in men with metastatic prostate cancer (mPC). Various methods have been used to identify SREs from claims data. The objective of this study was to provide a framework for measuring SREs from claims and compare SRE prevalence and cumulative incidence estimates based on alternative approaches in men with mPC. Methods Several claims-based approaches for identifying SREs were developed and applied to data for men aged [greater than or equal to] 66 years newly diagnosed with mPC between 2000 and 2009 in the SEER-Medicare datasets and followed through 2010 or until censoring. Post-diagnosis SREs were identified using claims that indicated spinal cord compression (SCC), pathologic fracture (PF), surgery to bone (BS), or radiation (suggestive of bone palliative radiation, RAD). To measure SRE prevalence, two SRE definitions were created: ‘base case’ (most commonly used in the literature) and ‘alternative’ in which different claims were used to identify each type of SRE. To measure cumulative incidence, we used the ‘base case’ definition and applied three periods in which claims were clustered to episodes: 14-, 21-, and 28-day windows. Results Among 8997 mPC patients, 46 % experienced an SRE according to the ‘base case’ definition and 43 % patients experienced an SRE according to the ‘alternative’ definition. Varying the code definition from ‘base case’ to ‘alternative’ resulted in an 8 % increase in the overall SRE prevalence. Using the 21-day window, a total of 12,930 SRE episodes were observed during follow up. Varying the window length from 21 to 28 days resulted in an 8 % decrease in SRE cumulative incidence (RAD: 10 %, PF: 8 %, SCC: 6 %, BS: 0.2 %). Conclusions SRE prevalence was affected by the codes used, with PF being most impacted. The overall SRE cumulative incidence was affected by the window length used, with RAD being most affected. These results underscore the importance of the baseline definitions used to study claims data when attempting to understand relevant clinical events such as SREs in the real world setting.
Collapse
Affiliation(s)
- Abdalla Aly
- Department of Pharmaceutical Health Services Research, University of Maryland, School of Pharmacy, Saratoga Building, 12th Floor, 220 Arch Street, Baltimore, MD, 21201, USA.
| | - Eberechukwu Onukwugha
- Department of Pharmaceutical Health Services Research, University of Maryland, School of Pharmacy, Saratoga Building, 12th Floor, 220 Arch Street, Baltimore, MD, 21201, USA.
| | - Corinne Woods
- Pharmaceutical Research Computing, University of Maryland, School of Pharmacy, Saratoga Building, 12th Floor, 220 Arch Street, Baltimore, MD, 21201, USA.
| | - C Daniel Mullins
- Department of Pharmaceutical Health Services Research, University of Maryland, School of Pharmacy, Saratoga Building, 12th Floor, 220 Arch Street, Baltimore, MD, 21201, USA.
| | - Young Kwok
- University of Maryland Medical Center, 22 S. Greene Street, Baltimore, MD, 21201, USA.
| | - Yi Qian
- Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA, 91320, USA.
| | - Jorge Arellano
- Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA, 91320, USA.
| | - Arun Balakumaran
- Amgen Inc., 1 Amgen Center Drive, Thousand Oaks, CA, 91320, USA.
| | - Arif Hussain
- University of Maryland Medical Center, 22 S. Greene Street, Baltimore, MD, 21201, USA.
| |
Collapse
|
12
|
Geng CJ, Liang Q, Zhong JH, Zhu M, Meng FY, Wu N, Liang R, Yuan BY. Ibandronate to treat skeletal-related events and bone pain in metastatic bone disease or multiple myeloma: a meta-analysis of randomised clinical trials. BMJ Open 2015; 5:e007258. [PMID: 26038356 PMCID: PMC4458633 DOI: 10.1136/bmjopen-2014-007258] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
OBJECTIVE Randomised controlled trials (RCTs) have given contradictory results about the efficacy and safety of ibandronate in treating metastatic bone disease (MBD) or multiple myeloma. This review meta-analysed the literature to gain a more comprehensive picture. DESIGN Systematic review and meta-analysis of ibandronate compared with placebo or zoledronate. DATA SOURCES PubMed, EMBASE and the Cochrane Library databases were systematically searched to identify RCTs published up to March 2015 evaluating ibandronate to treat MBD or multiple myeloma. REVIEW METHOD 10 RCTs involving 3474 patients were included. Six RCTs were placebo-controlled and four compared ibandronate with zoledronate. The studies included in this review were mainly from European countries. RESULTS Intravenous ibandronate (6 mg) or oral drug (50 mg) decreased the risk of skeletal-related events compared to placebo (risk ratio (RR) 0.80, 95% CI 0.71 to 0.90, p=0.002). It also reduced the bone pain score below baseline significantly more than did placebo at 96 weeks (weighted mean difference -0.41, 95% CI -0.56 to -0.27, p<0.001). The incidence of diarrhoea, nausea and adverse renal events was similar between the ibandronate and placebo groups, but ibandronate was associated with greater risk of abdominal pain. Ibandronate was associated with similar risk of skeletal-related events as another bisphosphonate drug, zoledronate (RR 1.02, 95% CI 0.82 to 1.26, p=0.87). The incidence of nausea, jaw osteonecrosis and fatigue was similar for the two drugs, but the incidence of adverse renal events was significantly lower in the ibandronate group. CONCLUSIONS Ibandronate significantly reduces the incidence of skeletal-related events and bone pain in patients with MBD or multiple myeloma relative to placebo. It is associated with a similar incidence of skeletal-related events as zoledronate.
Collapse
Affiliation(s)
- Chun-Jing Geng
- Department of Anesthesiology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, People's Republic of China
| | - Qian Liang
- Postgraduate School of Guangxi Medical University, Nanning, People's Republic of China
| | - Jian-Hong Zhong
- Hepatobiliary Surgery Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, People's Republic of China
| | - Min Zhu
- Department of Anesthesiology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, People's Republic of China
| | - Fan-Ying Meng
- Department of Anesthesiology, Affiliated Hospital of Chifeng University, Inner Mongolia Autonomous Region,Nanning, People's Republic of China
| | - Ning Wu
- Department of Anesthesiology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, People's Republic of China
| | - Rui Liang
- Department of Anesthesiology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, People's Republic of China
| | - Bin-Yi Yuan
- Out-patient Department, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, People's Republic of China
| |
Collapse
|
13
|
Hsu E, Murphy S, Chang D, Cohen SP. Expert opinion on emerging drugs: chronic low back pain. Expert Opin Emerg Drugs 2014; 20:103-27. [DOI: 10.1517/14728214.2015.993379] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
|
14
|
Bosscher MRF, van Leeuwen BL, Hoekstra HJ. Surgical emergencies in oncology. Cancer Treat Rev 2014; 40:1028-36. [PMID: 24933674 DOI: 10.1016/j.ctrv.2014.05.005] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2014] [Revised: 05/09/2014] [Accepted: 05/12/2014] [Indexed: 02/06/2023]
Abstract
An oncologic emergency is defined as an acute, potentially life threatening condition in a cancer patient that has developed as a result of the malignant disease or its treatment. Many oncologic emergencies are signs of advanced, end-stage malignant disease. Oncologic emergencies can be divided into medical or surgical. The literature was reviewed to construct a summary of potential surgical emergencies in oncology that any surgeon can be confronted with in daily practice, and to offer insight into the current approach for these wide ranged emergencies. Cancer patients can experience symptoms of obstruction of different structures and various causes. Obstruction of the gastrointestinal tract is the most frequent condition seen in surgical practice. Further surgical emergencies include infections due to immune deficiency, perforation of the gastrointestinal tract, bleeding events, and pathological fractures. For the institution of the appropriate treatment for any emergency, it is important to determine the underlying cause, since emergencies can be either benign or malignant of origin. Some emergencies are well managed with conservative or non-invasive treatment, whereas others require emergency surgery. The patient's performance status, cancer stage and prognosis, type and severity of the emergency, and the patient's wishes regarding invasiveness of treatment are essential during the decision making process for optimal management.
Collapse
Affiliation(s)
- M R F Bosscher
- Department of Surgical Oncology, University of Groningen, University Medical Center Groningen, HPC BA31, P.O. Box 30.001, 9700 RB Groningen, The Netherlands.
| | - B L van Leeuwen
- Department of Surgical Oncology, University of Groningen, University Medical Center Groningen, HPC BA31, P.O. Box 30.001, 9700 RB Groningen, The Netherlands.
| | - H J Hoekstra
- Department of Surgical Oncology, University of Groningen, University Medical Center Groningen, HPC BA31, P.O. Box 30.001, 9700 RB Groningen, The Netherlands.
| |
Collapse
|